Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02060773|
Recruitment Status : Unknown
Verified December 2012 by Xiaohua Qiu, Zhongda Hospital.
Recruitment status was: Recruiting
First Posted : February 12, 2014
Last Update Posted : February 12, 2014
To observe the effect of early goal directed therapy (EGDT) on hepatic perfusion in patients with septic shock.
Hypothesis: Hepatic perfusion did not improved after EGDT in patients with septic shock.
|Condition or disease|
Objective To observe the effect of early goal directed therapy (EGDT) on hepatic perfusion in patients with septic shock.
Methods A prospective observational study was carried out. The eligible patients were treated with the standard procedure of EGDT. The hemodynamic data were recorded. Oxygen metabolism and hepatic function were monitored. Indocyanine clearance test was applied to detect the hepatic perfusion. Hemodynamics, hepatic perfusion, oxygen metabolism and hepatic function were compared before treatment, after EGDT and 24 hours after EGDT.
|Study Type :||Observational|
|Official Title:||Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||February 2014|
|Estimated Study Completion Date :||February 2014|
- ICG-PDR and R15 before treatment, after EGDT and 24 hours after EGDT. [ Time Frame: 30 hours ]
- 28 days mortality [ Time Frame: 28 days ]Follow up to determine the mortality in 28 days after inclusion
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02060773
|Contact: Xiaohua Qiu, MDfirstname.lastname@example.org|
|Affiliated Zhongda Hospital of Southeast University||Recruiting|
|Nanjing, Jiangsu, China, 210009|
|Contact: Xiaohua Qiu, MD 0086-025-83262553 email@example.com|
|Principal Investigator: Xiwen Zhang, MD|
|Sub-Investigator: Xiaohua Qiu, MD|